• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ImmunoGen Reports Recent Progress and 2022 Financial Results

    3/1/23 6:30:00 AM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGN alert in real time by email

    Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium

    Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2 2023; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe

    Encouraging Safety and Efficacy Data from Pivekimab Sunirine Triplet in AML Presented in Oral Session at ASH 2022; Clinical Collaboration with Gilead Announced to Evaluate Pivekimab with Magrolimab in Relapsed/Refractory AML

    Announced a Global, Multi-Target License and Option Agreement of ImmunoGen's ADC Technology to Vertex; ImmunoGen to Receive a $15 Million Upfront Payment and is Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis

    Appointments of Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs, and Daniel Char as Chief Legal Officer, Further Strengthen Management Team

    Conference Call to be Held at 8:00 a.m. ET Today

    ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2022.

    "We significantly advanced the business on multiple fronts over the last 12 months, most notably with the accelerated approval and launch of ELAHERE for patients with platinum-resistant ovarian cancer," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "We have seen broad and deep adoption of ELAHERE to date, with FRα testing, managed care coverage, and provider access all exceeding our expectations. Building upon this progress and in line with our goal of obtaining full approval for ELAHERE in the US and expanding into Europe, we will imminently reach the requisite number of PFS events in the confirmatory MIRASOL trial and expect to announce top-line data in the second quarter. In parallel, we are pursuing our broader development program in support of moving ELAHERE into platinum-sensitive disease and positioning ELAHERE as the combination agent of choice in ovarian cancer."

    Enyedy continued, "Turning to our second pivotal program, pivekimab sunirine, we presented promising findings from our triplet expansion cohorts in AML in an oral presentation at ASH in December, and continued enrollment in the pivotal CADENZA trial in frontline BPDCN with top-line data in de novo patients anticipated in 2024. We are also progressing our earlier-stage portfolio with the completion of dose escalation in the Phase 1 study of IMGC936, while also having dosed the first patient in our Phase 1 trial for IMGN151 in January. Combining our commitment to advance our pipeline of novel ADCs along with driving the commercial uptake of ELAHERE in the US, we are well positioned for another exciting and productive year."

    RECENT PROGRESS

    ELAHERE (mirvetuximab soravtansine-gynx)

    • Received US Food and Drug Administration (FDA) accelerated approval of ELAHERE for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) on November 14, 2022.
    • Generated $2.6 million in net sales for the fourth quarter of 2022.
    • ELAHERE monotherapy and in combination with bevacizumab included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and compendium.

    Clinical Pipeline

    • Published manuscript on the safety and efficacy of mirvetuximab in PROC in the SORAYA trial in the Journal of Clinical Oncology.
    • Published manuscript on the safety and efficacy of mirvetuximab in combination with bevacizumab in PROC in Gynecologic Oncology.
    • Completed enrollment in PICCOLO, a single-arm study of mirvetuximab monotherapy in FRα-high recurrent platinum-sensitive ovarian cancer (PSOC).
    • Presented data from expansion cohorts in the Phase 1b/2 study evaluating the pivekimab sunirine (pivekimab) triplet with Vidaza® (azacitidine) and Venclexta® (venetoclax) in relapsed/refractory (R/R) and initial data in frontline unfit acute myeloid leukemia (AML) in an oral presentation at the 2022 American Society of Hematology (ASH) Annual Meeting in December.
    • Progressed the pivotal Phase 2 CADENZA study of pivekimab sunirine (pivekimab) in frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    • Completed dose escalation in the Phase 1 study of IMGC936 in multiple solid tumor types and initiated expansion cohorts in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
    • Enrolled the first patient in the Phase 1 study of IMGN151 in January 2023.

    Corporate Development

    • Announced a global, multi-target license and option agreement granting Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing in exchange for a $15 million upfront payment and up to $337 million in potential option exercise fees, development and commercial milestones, and tiered royalties on a per target basis.
    • Announced a clinical collaboration with Gilead to evaluate the safety and anti-leukemia activity of pivekimab in combination with magrolimab, a potential first-in-class CD47 inhibitor, in patients with R/R CD123-positive AML.
    • Appointed Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs, and Daniel Char, JD, as Senior Vice President and Chief Legal Officer.

    ANTICIPATED UPCOMING EVENTS

    • Report top-line data for MIRASOL in the second quarter of 2023.
    • Submit the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ELAHERE in FRα-high PROC in the second half of 2023 to support potential approval and launch.
    • Submit the supplemental Biologics License Application (sBLA) to the FDA in the second half of 2023 to support the conversion of the accelerated approval of ELAHERE to a full approval.
    • Our partner, Huadong Medicine, to submit the biologics license application (BLA) to the National Medical Products Administration (NMPA) of China for ELAHERE in FRα-high PROC in the second half of 2023 to support potential approval and launch.
    • Present efficacy data from the SORAYA trial by sequence of treatment and final overall survival analysis at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in March.
    • Report on the primary endpoint for PICCOLO before the end of 2023.
    • Complete enrollment of the efficacy evaluable cohort of de novo BPDCN patients in the pivotal phase 2 CADENZA study by the end of 2023.
    • Initiate the combination cohort of pivekimab with magrolimab in R/R AML in collaboration with Gilead in the second half of 2023.
    • Report dose escalation data in Phase 1 trial of IMGC936 and initial experience in expansion cohorts in the second quarter of 2023.

    FINANCIAL RESULTS

    Total revenues were $41.2 million for the quarter ended December 31, 2022 compared to $28.0 million for the quarter ended December 31, 2021, and $108.8 million for the year ended December 31, 2022 compared to $69.9 million for the year ended December 31, 2021. The increase in the quarter ended December 31, 2022 was primarily driven by one-time milestone payments achieved pursuant to the Company's license and collaboration agreements with Huadong Medicine and Viridian Therapeutics. In addition to greater partner milestones achieved, the increase for the current year was driven by one-time license fees received pursuant to agreements executed with Eli Lilly and Magenta Therapeutics in 2022, as well as greater amortization in 2022 of the $40.0 million upfront fee previously received pursuant to the Company's collaboration agreement with Huadong Medicine. The Company also recorded $2.6 million in net product revenue from sales of ELAHERE for the quarter and year ended December 31, 2022.

    Research and development expenses rose to $58.5 million for the quarter ended December 31, 2022 compared to $49.0 million for the quarter ended December 31, 2021, and $213.4 million for the year ended December 31, 2022 compared to $151.1 million for the year ended December 31, 2021. The increases in both periods were driven by greater personnel and temporary staffing costs, external manufacturing costs, and third-party service fees, including medical affairs' activities in support of the US commercial launch of ELAHERE in the fourth quarter of 2022, as well as greater clinical trial expenses. Additionally, research and development expenses for the year ended December 31, 2022 included $8.9 million of research costs to expand our ADC pipeline, inclusive of a one-time $7.5 million upfront fee paid to Oxford BioTherapeutics.

    Selling, general and administrative expenses were $42.1 million for the quarter ended December 31, 2022 compared to $13.6 million for the quarter ended December 31, 2021, and $116.1 million for the year ended December 31, 2022 compared to $43.8 million for the year ended December 31, 2021. The increases in both periods were due primarily to building our commercial infrastructure and capabilities, including personnel-related costs and sales and marketing activities in support of the US launch of ELAHERE in the fourth quarter of 2022.

    Net loss for the fourth quarter of 2022 was $59.0 million, or $0.23 per diluted share, compared to net loss of $37.2 million, or $0.17 per diluted share, for the fourth quarter of 2021. Net loss for the year ended December 31, 2022 was $222.9 million, or $0.88 per diluted share, compared to a net loss of $139.3 million, or $0.68 per diluted share, for the year ended December 31, 2021.

    ImmunoGen had $275.1 million in cash and cash equivalents as of December 31, 2022, compared with $478.8 million as of December 31, 2021. Cash used in operations was $229.8 million for the year ended December 31, 2022 compared with $169.4 million for the year ended December 31, 2021. Capital expenditures were $1.4 million in each of the years ended December 31, 2022 and 2021.

    During the quarter ended December 31, 2022, the Company sold 5.2 million shares of its common stock through its At-the-Market facility, generating net proceeds to the Company of $25.6 million.

    FINANCIAL GUIDANCE

    For 2023, ImmunoGen expects:

    • revenues, excluding product revenue from ELAHERE, between $30 million and $35 million; and
    • operating expenses between $310 million and $320 million.

    ImmunoGen expects to provide ELAHERE product revenue guidance later this year.

    Excluding anticipated ELAHERE and collaboration revenue, our level of cash and cash equivalents as of December 31, 2022, alone is not sufficient to meet our current operating plans through March 1, 2024. With the addition of forecasted ELAHERE product revenue and milestone payments under existing collaboration agreements, we expect these amounts combined with existing cash and cash equivalents will fund operations for more than 12 months from the date of this release. The Company intends to raise additional funds through equity, debt, or other financings.

    CONFERENCE CALL INFORMATION

    ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location.

    ABOUT ELAHERE™ (MIRVETUXIMAB SORAVTANSINE-GYNX)

    ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.

    ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

    This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Eye problems are common with ELAHERE and can be severe. ELAHERE also can cause severe or life-threatening inflammation of the lungs that may lead to death and patients may develop nerve problems called peripheral neuropathy during treatment. Please see full Prescribing Information, including Boxed Warning, and Medication Guide for ELAHERE.

    ABOUT IMMUNOGEN

    ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

    Learn more about who we are, what we do, and how we do it at www.immunogen.com.

    Vidaza®, and Venclexta® are registered trademarks of their respective owners. ELAHERE™ is a trademark of ImmunoGen, Inc.

    FORWARD-LOOKING STATEMENTS

    This press release includes forward-looking statements. These statements include, but are not limited to, ImmunoGen's expectations related to: the Company's revenues and operating expenses for 2023; the Company's anticipated cash runway; the Company's expectations regarding future financing activities; the occurrence, timing, and outcome of potential preclinical, clinical, and regulatory events related to, and the potential benefits of, the Company's product candidates, including, but not limited to: the commercialization of ELAHERE, the potential of ELAHERE to become the combination agent of choice, and the potential full approval of ELAHERE in the US and expansion to Europe; the timing and presentation of preclinical and clinical data on the Company's product candidates, including data from the MIRASOL trial, data from the CADENZA trial, data from the SORAYA trial, and data from the Phase 1 trial of IMGC936; and the Company's business and product development strategies. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the results of the ongoing MIRASOL trial may fail to support full approval of ELAHERE and, if not, additional studies may be required; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the timing and outcome of the Company's anticipated interactions with regulatory authorities; the risk that we may not be able to obtain adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties for ELAHERE in light of the FDA granting accelerated approval; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2023 and other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

    ImmunoGen, Inc. Reports Financial Results for the Quarter and Year Ended December 31, 2022

     
    IMMUNOGEN, INC.
    SELECTED FINANCIAL INFORMATION
    (in thousands, except per share amounts)
     
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Unaudited)
     

    December 31,

    December 31,

    2022

    2021

    ASSETS
     
    Cash and cash equivalents $

    275,138

    $

    478,750

    Other assets

    73,798

    47,015

     
    Total assets $

    348,936

    $

    525,765

     
    LIABILITIES AND SHAREHOLDERS' EQUITY
     
    Current portion of deferred revenue $

    13,856

    $

    44,351

    Other current liabilities

    108,002

    56,594

    Long-term portion of deferred revenue

    36,355

    47,717

    Other long-term liabilities

    34,897

    51,517

    Shareholders' equity

    155,826

    325,586

     
    Total liabilities and shareholders' equity $

    348,936

    $

    525,765

     
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Unaudited)

    Three Months Ended

    Year Ended

    December 31,

    December 31,

    2022

    2021

    2022

    2021

    Revenues:
    License and milestone fees $

    30,780

    $

    19,564

    $

    76,027

    $

    22,650

    Non-cash royalty revenue

    7,724

    8,040

    29,261

    46,808

    Product revenue, net

    2,554

    -

    2,554

    -

    Research and development support

    109

    388

    940

    398

     
    Total revenues

    41,167

    27,992

    108,782

    69,856

    Cost and operating expenses:
    Cost of sales

    176

    -

    176

    -

    Research and development

    58,485

    48,968

    213,370

    151,117

    Selling, general and administrative

    42,065

    13,578

    116,129

    43,812

     
    Total cost and operating expenses

    100,726

    62,546

    329,675

    194,929

    Loss from operations

    (59,559)

    (34,554)

    (220,893)

    (125,073)

    Non-cash interest expense on liability related to sale of future royalty & convertible bonds

    (971)

    (2,151)

    (4,165)

    (13,103)

    Interest expense on convertible bonds

    -

    -

    -

    (47)

    Other income (loss), net

    2,740

    (467)

    3,347

    (1,080)

    Loss before income taxes $

    (57,790)

    $

    (37,172)

    $

    (221,711)

    $

    (139,303)

    Income tax expense

    1,218

    -

    1,218

    -

    Net loss $

    (59,008)

    $

    (37,172)

    $

    (222,929)

    $

    (139,303)

     
    Basic and diluted net loss per common share $

    (0.23)

    $

    (0.17)

    $

    (0.88)

    $

    (0.68)

     
    Basic and diluted weighted average common shares outstanding

    254,405

    215,830

    253,361

    206,147

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005398/en/

    Get the next $IMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMGN

    DatePrice TargetRatingAnalyst
    12/1/2023$25.00 → $31.00Buy → Neutral
    Guggenheim
    11/20/2023$17.00Neutral
    Goldman
    11/9/2023$25.00Buy
    Deutsche Bank
    10/6/2023$16.00Perform
    Oppenheimer
    5/3/2023$6.00 → $16.00Neutral → Overweight
    Piper Sandler
    11/21/2022$10.00Buy
    Truist
    9/9/2022$8.00Overweight
    Barclays
    3/21/2022$9.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ImmunoGen downgraded by Guggenheim with a new price target

      Guggenheim downgraded ImmunoGen from Buy to Neutral and set a new price target of $31.00 from $25.00 previously

      12/1/23 7:33:23 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on ImmunoGen with a new price target

      Goldman initiated coverage of ImmunoGen with a rating of Neutral and set a new price target of $17.00

      11/20/23 7:31:54 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on ImmunoGen with a new price target

      Deutsche Bank initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $25.00

      11/9/23 6:40:12 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:55 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Peterson Kristine

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thackray Helen M. returned 3,074 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:47:26 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2024 - FDA Roundup: March 26, 2024

      For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

      3/26/24 3:38:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

      3/22/24 1:48:21 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

      11/15/22 5:01:07 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    SEC Filings

    See more
    • SEC Form 15-12G filed by ImmunoGen Inc.

      15-12G - ImmunoGen, Inc. (0000855654) (Filer)

      2/22/24 4:15:19 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:33:11 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:32:20 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen's Senior Vice President and Chief Financial Officer, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units ("RSUs") covering 51,625 shares of its common stock under the Inducement Plan to Ms. White. The Inducement Plan is used exclusively for the grant of equity awards t

      9/18/23 5:00:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

      New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this m

      1/22/25 11:05:00 AM ET
      $IMGN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 5:01:40 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 4:26:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/13/24 5:06:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Financials

    Live finance-specific insights

    See more
    • AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

      Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billionAbbVie to hold an investor conference call at 8:00 a.m. CTNORTH CHICAGO

      11/30/23 7:30:00 AM ET
      $ABBV
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

      Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer Conference Call to be Held at 8:00 a.m. E

      11/2/23 6:30:00 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

      ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN

      10/19/23 4:01:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care